Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Maribavir Pediatric Formulation
NCT05918822Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maribavir in cytomegalovirus infection (CMV) (8 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Jul 2023; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05918822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918822.